Inhalation

INH0426

Issue link: https://www.e-digitaleditions.com/i/1544305

Contents of this Issue

Navigation

Page 36 of 47

This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. EXTRA FOCUS Product Development This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Inhalation April 2026 35 Design and supply of inhalers for future respiratory therapies Merxin Ltd designs and supplies dry powder and soft mist inhalers that support established and emerg- ing inhaled therapies. We are proudly embracing the future of oncology therapies with our MRX004 SMI device and our work with CorriX erapeutics on lung cancer treatments via direct pulmonary delivery. We also support the industry's transition from HFA pMDIs to lower global warming potential inhalation technologies with MRX004, maintaining treatment efficacy while reducing environmental impact. As we celebrate our 10th anniversary, we are proud to say that we are the only inhaler developer with 3 very different technologies partnered in the generic space and 1 commercial launch. Partner with Merxin Ltd to evolve your respiratory pipeline. Merxin Ltd UK: +44 1553 403070 info@merxin.com www.merxin.com End-to-end inhaled and nasal drug product development Bespak, the specialist inhalation CDMO, supports every stage of inhaled and nasal drug-device product development. Its expertise spans pMDIs, DPIs, SMIs and unit- and multi-dose nasal drug delivery. From early feasibility and formulation support to device design, clinical supply and full industrialization, Bespak delivers an integrated service. A risk-based, design-for-manufacture approach reduces complexity and speeds progress. With lab, pilot and commercial capabilities for next-generation low carbon pMDIs, Bespak helps partners meet sustainability goals while achieving regulatory and commercial success. Bespak UK: +44 1477 537112 enquiries@bespak.com www.bespak.com Spray characterization for the low-GWP era Low-GWP propellants are reshaping pMDI refor- mulation strategy. Changes in vapor pressure, plume dynamics and suspension behavior demand renewed spray characterization to ensure performance equiva- lence and stability. Proveris Laboratories can deliver detailed spray pattern, plume geometry, plume front velocity, APSD and shaking studies to sup- port regulatory- ready data and reduce reformulation risk. We help sponsors move confidently from legacy HFAs to next-generation propellants. Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proveris.com

Articles in this issue

Links on this page

view archives of Inhalation - INH0426